Oslo, Norway, 21 November 2016 - Serodus ASA (OSE: SER) held an extraordinary general meeting on 21 November 2016 at 15:00 PM CET.

The Extraordinary General Assembly Meeting of Serodus ASA today adopted all the items as proposed on the agenda distributed 1 November 2016.

The minutes of the Extraordinary General Assembly Meeting is attached. For more information please consult www.serodus.com or contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

Serodus ASA is a Scandinavian drug development company, focusing on new therapeutic products for the treatment of diabetes and diabetic comorbidities with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.com.

Serodus ASA published this content on 21 November 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 November 2016 11:12:09 UTC.

Original documenthttp://www.serodus.com/News/2016/Extraordinary-general-meeting-held2

Public permalinkhttp://www.publicnow.com/view/C11DD04C6F784DA610C4327EB8A451E64947C6E8